What is the 13F Pro Quality Score for TBPH?

13F Pro ranks Theravance Biopharma, Inc. (TBPH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TBPH's current score at https://13fpro.ai/research/TBPH (free sign-up required for the full ranking).

Where does 13F Pro source TBPH data?

All Theravance Biopharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. Theravance Biopharma, Inc. files with the SEC under CIK 1583107. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TBPH in?

Theravance Biopharma, Inc. (TBPH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives TBPH's revenue?

Per Theravance Biopharma, Inc.'s latest 10-Q filed with the SEC on 2026-05-07, the biggest revenue drivers are: Viatris collaboration agreement ($17.7M, +15% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/TBPH.

What are TBPH's largest expenses?

Theravance Biopharma, Inc.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($17.7M, -4% YoY); Research and development ($5.8M, -49% YoY); Restructuring expenses ($3.6M, New in Q1 2026). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is TBPH research updated on 13F Pro?

TBPH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Theravance Biopharma, Inc.(TBPH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1583107 TBPH stock profile & AI dashboard →

13F Pro Quality Score

68.9/100

Rank #398 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

81.4/100

Profitability

95.2/100

Balance Sheet

82.4/100

Earnings Quality

30.0/100

Free Cash Flow

97.9/100

Institutional Flow

44.4/100

Revenue Scale

15.1/100

Dilution Risk

10.9/100

TBPH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Theravance Biopharma, Inc. (TBPH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TBPH at 68.9/100 on a 32-signal composite quality model, placing it at rank #398 of 2,879 stocks — the top 25% of the AI-ranked universe. TBPH scores in the top quartile across free cash flow (97.9), profitability (95.2), balance sheet strength (82.4). Areas of concern include revenue scale (15.1) and earnings quality (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Theravance Biopharma, Inc. reports quarterly revenue of $17.7M, net income of $-4.9M, free cash flow of $73.3M. Top institutional holders of TBPH by reported 13-F value include Madison Avenue Partners,, Weiss Asset Management, Newtyn Management,, based on the most recent SEC filings. TBPH trades on the Nasdaq exchange and files with the SEC under CIK 1583107. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TBPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Theravance Biopharma, Inc. directly from SEC EDGAR. Theravance Biopharma, Inc.'s 13F Pro composite quality score has ranged between 8 and 69 since 2021, currently 68.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

What's Driving TBPH's Business? Latest 10-Q Breakdown

✓ 27/27 datapoints verified

AI-extracted from Theravance Biopharma, Inc.'s 10-Q filed 2026-05-07 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q1 revenue of $17.7M from Viatris collaboration, but net loss of $4.9M; company winding down ampreloxetine after Phase 3 failure and restructuring to cut 50% of staff.

Biggest Revenue Drivers

Total revenue: $17.7M+15% YoY

Viatris collaboration agreement$17.7M+15% YoY

Company's 35% profit share of YUPELRI net sales; YUPELRI total net sales grew 7% YoY driven by customer demand growth and improved net pricing.

Largest Expense Items

Selling, general and administrative$17.7M-4% YoY

Includes share-based compensation of $2.8M; decline attributable to cost savings from March 2026 restructuring.

Research and development$5.8M-49% YoY

Decrease primarily due to wind-down of ampreloxetine CYPRESS trial and restructuring cost savings.

Restructuring expenses$3.6MNew in Q1 2026

One-time cash severance costs ($2.6M) and equity award modification ($1.0M) for ~50% headcount reduction; 45 employees departed on March 31, 2026.

Margins: Operating margin severely negative at -54% (loss from operations of $9.5M on revenue of $17.7M), driven by fixed SG&A and R&D infrastructure costs that dwarf near-term revenue. Restructuring is expected to reduce annual operating expenses by ~$70M (60% reduction from 2025's $111.1M), with full run-rate savings beginning Q3 2026.

Watch Items from the Filing

Ampreloxetine Phase 3 CYPRESS study failed primary endpoint; company decided to wind down program. Ceased recognizing interest expense on $32.8M contingent royalty liability to Royalty Pharma as of Q1 2026.
Strategic Review Committee accelerated evaluation of alternatives to maximize shareholder value, including potential sale of company, with no assurance of consummation or timeline disclosed.
Organizational restructuring announced March 3, 2026: reducing 90 employees by ~50%, winding down R&D function, cutting G&A by ~50%. Estimated total cash costs $5.0M–$7.0M and non-cash costs $3.5M–$4.5M through Q3 2026.
YUPELRI patent litigation with seven generic companies settled; licensed launch date of April 23, 2039 granted to all generic competitors, subject to DOJ/FTC review.
Cash, equivalents and marketable securities of $394.7M as of March 31, 2026; company expects liquidity sufficient for at least 12 months. Received $25.0M Viatris milestone (January 2026) and $50.0M TRELEGY milestone from Royalty Pharma (February 2026).

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$17.7M

Net Income

Q1 2026

$-4.9M

Free Cash Flow

Q1 2026

$73.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+66.9% YoY

$107.5MFY 2025

FY21 $55.3MFY22 $51.3MFY24 $64.4MFY25 $107.5M

Net Income

+287.7% YoY

$105.9MFY 2025

FY21 $-199.4MFY22 $872.1MFY24 $-56.4MFY25 $105.9M

Operating Income

+92.3% YoY

$-3.6MFY 2025

FY21 $-257.8MFY22 $-92.0MFY24 $-46.9MFY25 $-3.6M

EPS (Diluted)

+279.1% YoY

$2.06FY 2025

FY21 $-2.87FY22 $11.85FY24 $-1.15FY25 $2.06

Total Assets

+37.1% YoY

$485.6MFY 2025

FY21 $374.8MFY22 $607.4MFY24 $354.2MFY25 $485.6M

Total Debt

—FY 2025

FY21 $616.3MFY22 —FY24 —FY25 —

Op. Cash Flow

+2168.0% YoY

$238.5MFY 2025

FY21 $-207.9MFY22 $-187.0MFY24 $-11.5MFY25 $238.5M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$107.5M +66.9%	$64.4M +25.4%	$51.3M -7.2%	$55.3M -23.0%	$71.9M -2.1%	$73.4M
Net Income	$105.9M +287.7%	$-56.4M -106.5%	$872.1M +537.3%	$-199.4M +28.3%	$-278.0M -17.6%	$-236.5M
Operating Income	$-3.6M +92.3%	$-46.9M +48.9%	$-92.0M +64.3%	$-257.8M +13.4%	$-297.6M -18.1%	$-251.9M
EPS (Diluted)	$2.06 +279.1%	$-1.15 -109.7%	$11.85 +512.9%	$-2.87 +35.7%	$-4.46 -4.9%	$-4.25
Total Assets	$485.6M +37.1%	$354.2M -41.7%	$607.4M +62.1%	$374.8M -20.1%	$469.1M +14.7%	$408.8M
Total Debt	—	—	—	$616.3M -0.5%	$619.2M +36.1%	$455.0M
Operating Cash Flow	$238.5M +2168.0%	$-11.5M +93.8%	$-187.0M +10.0%	$-207.9M +17.0%	$-250.4M -5.1%	$-238.2M

AI Insight: TBPH Financial Trends

TBPH's first operating profit in six quarters arrived in Q4 2025 at $20M, but Q1 2026 reverted to a -$9M operating loss, signaling the profitability inflection is fragile.

• Revenue nearly tripled from Q2 2024 ($14M) to Q4 2025 ($46M), though Q1 2026 dropped back to $18M, suggesting lumpy, non-recurring components.

• Q4 2025 delivered the only operating profit ($20M) across the eight-quarter window; all other quarters posted operating losses ranging from -$3M to -$16M.

• Equity strengthened from $194M in Q2 2024 to $297M in Q4 2025 and held at $291M in Q1 2026, aided by episodic large net income gains.

• Operating cash flow is highly volatile: swinging from -$7M in Q3 2025 to +$208M in Q2 2025 and +$73M in Q1 2026, masking underlying burn.

⚠ Operating losses resumed at -$9M in Q1 2026 after the sole profitable quarter (Q4 2025 at $20M); sustainable profitability is unconfirmed.

⚠ Net income spikes in Q2 2025 ($55M) and Q4 2025 ($61M) far exceed operating income, implying below-the-line items driving results — monitor source and recurrence.

⚠ Debt data is absent across all periods; capital structure and leverage capacity remain opaque and warrant disclosure scrutiny.

AI Insight: TBPH Ratio Trends

TBPH swung to TTM operating profitability at 1.2% after years of deep losses, but Q1 2026 quarter alone reverted sharply to -53.6% operating margin, signaling extreme earnings volatility.

• Operating margin improved dramatically from -110.2% in Q2 2024 to a positive 1.2% on a TTM basis through Q1 2026.

• Q4 2025 was an exceptional quarter: operating margin hit 43.6%, ROA reached 50.3%, and ROIC turned positive at 27.0%.

• Q1 2026 reversed sharply — operating margin fell to -53.6% and ROIC dropped to -13.1%, unwinding Q4 2025 gains.

• D/E data is absent across all periods, limiting leverage assessment for a company with persistent operating losses.

⚠ Q1 2026 operating margin collapsed to -53.6% from Q4 2025's +43.6% — determine whether Q4 was a one-off event.

⚠ TTM net profit margin of 104.3% is heavily distorted by Q4 2025; underlying quarterly earnings remain highly unstable.

⚠ ROIC has only briefly turned positive (Q4 2025: 27.0%) amid a sustained negative trend — durability is unproven.

Get alerted when TBPH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Theravance Biopharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TBPH

Madison Avenue Partners, LP
$154.4M9,511,150 sh
Weiss Asset Management LP
$121.0M7,457,060 sh
Newtyn Management, LLC
$78.6M4,841,629 sh
BlackRock, Inc.
$69.7M4,296,290 sh
Irenic Capital Management LP
$44.8M2,760,948 sh
VANGUARD CAPITAL MANAGEMENT LLC
$29.0M1,783,753 sh
STATE STREET CORP
$21.1M1,297,323 sh
TWO SIGMA INVESTMENTS, LP
$20.4M1,258,497 sh
GEODE CAPITAL MANAGEMENT, LLC
$18.5M1,137,462 sh
DIMENSIONAL FUND ADVISORS LP
$16.0M983,615 sh

Fund	Value	Shares
Madison Avenue Partners, LP	$154.4M	9,511,150
Weiss Asset Management LP	$121.0M	7,457,060
Newtyn Management, LLC	$78.6M	4,841,629
BlackRock, Inc.	$69.7M	4,296,290
Irenic Capital Management LP	$44.8M	2,760,948
VANGUARD CAPITAL MANAGEMENT LLC	$29.0M	1,783,753
STATE STREET CORP	$21.1M	1,297,323
TWO SIGMA INVESTMENTS, LP	$20.4M	1,258,497
GEODE CAPITAL MANAGEMENT, LLC	$18.5M	1,137,462
DIMENSIONAL FUND ADVISORS LP	$16.0M	983,615

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TBPH on your watchlist

Track score changes the day Theravance Biopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TBPH a good stock to buy?

13F Pro's AI-powered analysis of Theravance Biopharma, Inc. (TBPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TBPH are available on the TBPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own TBPH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TBPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Theravance Biopharma, Inc.'s investment landscape.